258875-77-3

Upstream product

• 26870-36-0 2-(4-hydroxyphenyl)benzo[b]furan 
• 109-64-8 1,3-dibromo-propane 
• 19234-04-9 2-(p-methoxyphenyl)-benzo[b]furan 
• 70340-04-4 (2-hydroxybenzyl)triphenylphosphonium bromide 
• 90-02-8 salicylaldehyde 
• 90-01-7 salicylic alcohol 
• 100-07-2 4-methoxy-benzoyl chloride 

Relevant academic research and scientific papers

A short synthesis of the β-amyloid (Aβ) aggregation inhibitor 3-p-toluoyl-2-[4'-(3-diethylaminopropoxy)-phenyl]-benzofuran.

A short and convenient synthesis of 3-p-toluoyl-2-[4'-(3-diethylaminopropoxy)-phenyl]-benzofuran, an inhibitor of the aggregation of β-amyloid, which is thought to be the underlying cause of Alzheimer's disease, is described.

Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids

A series of berberine-phenyl-benzoheterocyclic (26-29) and tacrine-phenyl-benzoheterocyclic hybrids (44-46) were synthesised and evaluated as multifunctional anti-Alzheimer's disease agents. Compound 44b, tacrine linked with phenyl-benzothiazole by 3-carbon spacers, was the most potent AChE inhibitor with an IC50 value of 0.017 μM. This compound demonstrated similar Aβ aggregation inhibitory activity with cucurmin (51.8% vs 52.1% at 20 μM, respectively), indicating that this hybrid is an excellent multifunctional drug candidate for AD.